SG11201907032RA - Amino pyrimidine compounds useful as ssao inhibitors - Google Patents

Amino pyrimidine compounds useful as ssao inhibitors

Info

Publication number
SG11201907032RA
SG11201907032RA SG11201907032RA SG11201907032RA SG11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA
Authority
SG
Singapore
Prior art keywords
indiana
indianapolis
box
international
pct
Prior art date
Application number
SG11201907032RA
Inventor
Mengyang Fan
Luoheng Qin
Yi Wei
Guoqiang Zhou
Jingye Zhou
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63169081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907032R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201907032RA publication Critical patent/SG11201907032RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT omit IIl °nolo onm iflo oimIE (10) International Publication Number WO 2018/151985 Al (51) International Patent Classification: A61K 31/506 (2006.01) A61P 1/16 (2006.01) CO7D 239/47 (2006.01) (21) International Application Number: PCT/US2018/017152 (22) International Filing Date: 07 February 2018 (07.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/000157 14 February 2017 (14.02.2017) CN PCT/CN2017/117791 21 December 2017 (21.12.2017) CN (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (71) Applicant (for MG only): LILLY CHINA RESEARCH AND DEVELOPMENT CO., LTD [CN/CN]; 780 Cailun Road, Rm. 819, Zhangjiang High Technology Park, Pudong New Area, Shanghai 20000 (CN). (72) Inventors: FAN, Mengyang; c/o Eli Lilly And Compa- ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). QIN, Luoheng; c/o Eli Lilly And Company, P.O. Box 6288, Indianaoplis, Indiana 46206-6288 (US). WEI, Yi; c/ o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). ZHOU, Guoqiang; c/o Eli Lil- ly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). ZHOU, Jingye; c/o Eli Lilly And Com- pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agent: MYERS, James B. et al.; ELI LILLY AND COM- PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) In (54) Title: AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS 00 1-1 NH 2 1-1 (57) : The present invention provides compounds of the formula below, pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.
SG11201907032RA 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors SG11201907032RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2017/000157 WO2018148856A1 (en) 2017-02-14 2017-02-14 Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
PCT/CN2017/117791 WO2018149226A1 (en) 2017-02-14 2017-12-21 Amino pyrimidine compounds useful as ssao inhibitors
PCT/US2018/017152 WO2018151985A1 (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors

Publications (1)

Publication Number Publication Date
SG11201907032RA true SG11201907032RA (en) 2019-08-27

Family

ID=63169081

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913492YA SG10201913492YA (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors
SG11201907032RA SG11201907032RA (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913492YA SG10201913492YA (en) 2017-02-14 2018-02-07 Amino pyrimidine compounds useful as ssao inhibitors

Country Status (13)

Country Link
US (2) US10278970B2 (en)
EP (1) EP3582780B1 (en)
JP (2) JP7030827B2 (en)
KR (1) KR20190117007A (en)
CN (2) CN108778278B (en)
AU (1) AU2018221322B2 (en)
CA (1) CA3052044A1 (en)
DK (1) DK3582780T3 (en)
ES (1) ES2897666T3 (en)
IL (1) IL268625A (en)
MX (1) MX2019009501A (en)
SG (2) SG10201913492YA (en)
WO (3) WO2018148856A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
CN109251166B (en) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine
CN109810041B (en) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof
CN109988106B (en) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
CN110938059A (en) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 Preparation and application of aminourea sensitive amine oxidase inhibitor
WO2020063854A1 (en) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 Quinoline-based derivatives as vap-1 inhibitors
CN112955214A (en) * 2018-10-29 2021-06-11 勃林格殷格翰国际有限公司 Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof
CR20210216A (en) 2018-10-29 2021-06-24 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP2022517085A (en) * 2019-01-11 2022-03-04 南京薬捷安康生物科技有限公司 Halogenated allylamine compounds and their applications
CN111471037B (en) * 2019-01-23 2023-02-10 药捷安康(南京)科技股份有限公司 Allylamine compound and application thereof
MX2022005199A (en) 2019-10-29 2022-08-04 Eccogene Shanghai Co Ltd Ssao inhibitors and use thereof.
CN113149957A (en) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 Preparation and application of aminourea sensitive amine oxidase inhibitor
AU2021332217A1 (en) * 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123469A1 (en) 2007-03-30 2008-10-16 Japan Tobacco Inc. Six-membered amide compound and use thereof
US20100197692A1 (en) 2007-07-20 2010-08-05 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2706465A1 (en) * 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
US20110014558A1 (en) 2009-07-15 2011-01-20 Kabushiki Kaisha Toshiba Developing agent and method for producing the same
EP2479165B1 (en) 2009-09-16 2017-10-25 Astellas Pharma Inc. Glycine compound
JP2011136942A (en) 2009-12-28 2011-07-14 Kowa Co Novel substituted pyrimidine derivative and medicine comprising the same
ES2628850T3 (en) * 2011-03-15 2017-08-04 Astellas Pharma Inc. Guanidine compound
SI2844637T1 (en) * 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
AU2013344603B2 (en) 2012-11-16 2017-07-06 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
US8962641B2 (en) * 2013-04-17 2015-02-24 Boehringer Ingelheim International Gmbh Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
JP6378752B2 (en) 2013-05-17 2018-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018148856A1 (en) 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors

Also Published As

Publication number Publication date
US20180296560A1 (en) 2018-10-18
JP2022068325A (en) 2022-05-09
WO2018148856A1 (en) 2018-08-23
US10278970B2 (en) 2019-05-07
JP2020507589A (en) 2020-03-12
CN108778278A (en) 2018-11-09
US10471060B2 (en) 2019-11-12
JP7247389B2 (en) 2023-03-28
KR20190117007A (en) 2019-10-15
WO2018151985A1 (en) 2018-08-23
JP7030827B2 (en) 2022-03-07
CN108778278B (en) 2022-01-28
SG10201913492YA (en) 2020-03-30
AU2018221322A1 (en) 2019-08-15
IL268625A (en) 2019-10-31
US20190275041A1 (en) 2019-09-12
DK3582780T3 (en) 2021-11-01
CA3052044A1 (en) 2018-08-23
MX2019009501A (en) 2019-11-05
WO2018149226A1 (en) 2018-08-23
CN114369095A (en) 2022-04-19
EP3582780B1 (en) 2021-10-13
AU2018221322B2 (en) 2022-04-14
EP3582780A1 (en) 2019-12-25
ES2897666T3 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201907846VA (en) Therapeutic rna
SG11201909011PA (en) Niraparib compositions
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201906163TA (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201805001UA (en) Method of treating influenza a
SG11201901457TA (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201908660RA (en) N-substituted indole derivatives